All In Biotech

Drug Trial Radar · NCT04022304

Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N

A Randomised, Double-blind, Three-period, Partially Replicated Crossover, Euglycaemic Glucose Clamp Study in Healthy Volunteers to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity of Biocon Insulin N and Humulin® N

Last checked: Nov 20, 2026Latest source record: Jan 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jun 15, 2019

Primary completion

Dec 21, 2019

Study completion Dec 27, 2019

Sponsor

Lead sponsor
Biocon LimitedIndustry
Sponsor type
Industry
Collaborators
Profil Institut für Stoffwechselforschung GmbH
First posted
Jul 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single-centre, randomised, double-blind, three-period, six-sequence, partially replicated design, crossover trial in healthy subjects

Conditions

  • Healthy Volunteer

Interventions

  • Biocon Insulin NBiological

    Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).

  • Humulin® NBiological

    Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary PK endpoint: area under the insulin concentration curve(AUCins).0-24hTime frame: 0-24hour
  2. Primary PK endpoint: maximum observed insulin concentration(Cins.max)Time frame: 0-24hour
  3. PD endpoint:area under the glucose infusion rate curve(AUCGIR)0-24hTime frame: 0-24hour
  4. PD endpoint:maximum observed glucose infusion rate (GIRmax)Time frame: 0-24hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.